Trials / Completed
CompletedNCT00079612
Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer
Randomized Discontinuation Study of BAY 43-9006 in Patients With Advanced Refractory Cancer.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 501 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to: * Find out if BAY 43-9006 prevents the growth of tumors * For patients who have stable cancer status after 3 months of treatment if it is safer and/or more effective to continue to give BAY 43-9006 or to stop giving BAY 43-9006 at that time. * Find out how long the effect of BAY 43-9006 is on tumors. To assess the safety of BAY 43-9006 (sorafenib) in the treatment of advanced refractory cancers. * Measure the amount of BAY 43-9006 and some of its targets in the blood stream in some patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib (Nexavar, BAY43-9006) | 800mg daily (2x 400mg tabs) |
| DRUG | Placebo | 2x 400mg tabs daily |
Timeline
- Start date
- 2002-09-01
- Completion
- 2007-01-01
- First posted
- 2004-03-11
- Last updated
- 2014-12-19
Locations
7 sites across 2 countries: United States, United Kingdom
Source: ClinicalTrials.gov record NCT00079612. Inclusion in this directory is not an endorsement.